A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
收藏DataCite Commons2025-07-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011558/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
提供机构：
Vivli
创建时间：
2025-06-30
